New biweekly shot could help control blood sugar in type 2 diabetes
NCT ID NCT06254014
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests a new drug called JY09 in 270 adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants receive either JY09 or a placebo injection every two weeks for up to 54 weeks. The main goal is to see if JY09 lowers HbA1c (a measure of blood sugar control) after 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JY09 (Exendin-4 Fc fusion protein injection)
- What this could lead to
- If it works, JY09 could offer a new biweekly injection option to help control blood sugar in people with type 2 diabetes.
- What could go wrong
- This is a phase 3 trial, but it's still testing safety and efficacy against placebo. Results may not apply to all diabetes patients, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the speed of blood sugar drop harm the eyes? a study puts it to the test.
- Fig leaf tea may shield kidneys from diabetes damage — a trial puts it to the test
- Can a nasal spray of insulin shield the aging brain from Post-Surgery confusion?
- Smartphone app could improve blood sugar control in type 2 diabetes
- Personalizing kidney treatment: can biomarkers predict who benefits from finerenone?
- Diabetes drug class may change how the bladder behaves